BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 7654933)

  • 21. Fibrinogen Barcelona II: a new case of A alpha 16 Arg----His substitution.
    Borrell M; Vila L; Solá J; Coll I; Fontcuberta J
    Haemostasis; 1990; 20(1):1-7. PubMed ID: 2323678
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular basis of fibrinogen Naples associated with defective thrombin binding and thrombophilia. Homozygous substitution of B beta 68 Ala----Thr.
    Koopman J; Haverkate F; Lord ST; Grimbergen J; Mannucci PM
    J Clin Invest; 1992 Jul; 90(1):238-44. PubMed ID: 1634610
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fibrinogen Lima. A new dysfibrinogenaemia with a high-molecular-weight alpha-chain and effective polymerization.
    Arocha-Piñango CL; Rodriguez S; Nagy H; Perez Requejo JL
    Blood Coagul Fibrinolysis; 1990 Oct; 1(4-5):561-5. PubMed ID: 2133234
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fibrinogen Oviedo I. A new Spanish dysfibrinogenaemia.
    Fernández FJ; Rodríguez Pinto C; Páramo J; Cuesta B; Collado M; Rocha E
    Blood Coagul Fibrinolysis; 1990 Oct; 1(4-5):571-5. PubMed ID: 2133236
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Two novel mutations in the fibrinogen γ nodule.
    Kotlín R; Pastva O; Stikarová J; Hlaváčková A; Suttnar J; Chrastinová L; Riedel T; Salaj P; Dyr JE
    Thromb Res; 2014 Oct; 134(4):901-8. PubMed ID: 25074738
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fibrinogen anomalies and disease. A clinical update.
    Galanakis DK
    Hematol Oncol Clin North Am; 1992 Oct; 6(5):1171-87. PubMed ID: 1400080
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fibrinogen Ledyard (A alpha Arg16----Cys): biochemical and physiologic characterization.
    Lee MH; Kaczmarek E; Chin DT; Oda A; McIntosh S; Bauer KA; Clyne LP; McDonagh J
    Blood; 1991 Oct; 78(7):1744-52. PubMed ID: 1912564
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gene analyses of abnormal fibrinogens with a mutation in the gamma chain.
    Mimuro J; Muramatsu S; Maekawa H; Sakata Y; Kaneko M; Yoshitake S; Okuma M; Ito Y; Takeda Y; Matsuda M
    Int J Hematol; 1992 Oct; 56(2):129-34. PubMed ID: 1421174
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fibrinogen Matsumoto II: gamma 308 Asn-->Lys (AAT-->AAG) mutation associated with bleeding tendency.
    Okumura N; Furihata K; Terasawa F; Ishikawa S; Ueno I; Katsuyama T
    Br J Haematol; 1996 Sep; 94(3):526-8. PubMed ID: 8790154
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fibrinogen Matsumoto I: a gamma 364 Asp-->His (GAT-->CAT) substitution associated with defective fibrin polymerization.
    Okumura N; Furihata K; Terasawa F; Nakagoshi R; Ueno I; Katsuyama T
    Thromb Haemost; 1996 Jun; 75(6):887-91. PubMed ID: 8822581
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fibrinogen Guarenas I: partial characterization of a new dysfibrinogenemia with an altered rate of fibrinopeptide release and an impaired polymerization.
    Lundberg UG; Rodriguez S; Marchi R; Ruiz-Saez A; Arocha-Piñango CL
    Thromb Res; 1995 Apr; 78(2):95-106. PubMed ID: 7482436
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fibrinogen Poissy II (gammaN361K): a novel dysfibrinogenemia associated with defective polymerization and peptide B release.
    Mathonnet F; Guillon L; Detruit H; Mazmanian GM; Dreyfus M; Alvarez JC; Giudicelli Y; de Mazancourt P
    Blood Coagul Fibrinolysis; 2003 Apr; 14(3):293-8. PubMed ID: 12695754
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fibrinogen Bern I: substitution gamma 337 Asn-->Lys is responsible for defective fibrin monomer polymerization.
    Steinmann C; Reber P; Jungo M; Lämmle B; Heinemann G; Wermuth B; Furlan M
    Blood; 1993 Oct; 82(7):2104-8. PubMed ID: 8400260
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of fibrinogen D domain intermolecular association sites in the polymerization of fibrin and fibrinogen Tokyo II (gamma 275 Arg-->Cys).
    Mosesson MW; Siebenlist KR; DiOrio JP; Matsuda M; Hainfeld JF; Wall JS
    J Clin Invest; 1995 Aug; 96(2):1053-8. PubMed ID: 7635941
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analysis of plasmin generation and clot lysis of plasma fibrinogen purified from a heterozygous dysfibrinogenemia, BbetaGly15Cys (Hamamatsu II).
    Kamijyo Y; Hirota-Kawadobora M; Yamauchi K; Terasawa F; Honda T; Ikeya M; Okumura N
    Blood Coagul Fibrinolysis; 2009 Dec; 20(8):726-32. PubMed ID: 19809304
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Normal plasmic cleavage of the gamma-chain variant of "fibrinogen Saga" with an Arg-275 to His substitution.
    Yamazumi K; Terukina S; Onohara S; Matsuda M
    Thromb Haemost; 1988 Dec; 60(3):476-80. PubMed ID: 2976995
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Three abnormal fibrinogen variants with the same amino acid substitution (gamma 275 Arg----His): fibrinogens Bergamo II, Essen and Perugia.
    Reber P; Furlan M; Henschen A; Kaudewitz H; Barbui T; Hilgard P; Nenci GG; Berrettini M; Beck EA
    Thromb Haemost; 1986 Dec; 56(3):401-6. PubMed ID: 3563970
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel fibrinogen variant (fibrinogen Seoul II; AalphaGln328Pro) characterized by impaired fibrin alpha-chain cross-linking.
    Park R; Doh HJ; An SS; Choi JR; Chung KH; Song KS
    Blood; 2006 Sep; 108(6):1919-24. PubMed ID: 16735602
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fibrinogen Cordoba I: A gammaArg 275 His substitution associated with defective polymerization.
    Guglielmone HA; Minoldo S; Jarchum GD; Daga DA; Bocco JL
    Thromb Res; 2007; 121(3):429-30. PubMed ID: 17604827
    [No Abstract]   [Full Text] [Related]  

  • 40. [Functional study of abnormal fibrinogen caused by Arg275His mutation in fibrinogen γ chain].
    Zhou JY; Wang XF; Ding QL; Xu GQ; Zhang LW; Dai J; Lu YL; Xi XD; Wang HL
    Zhonghua Xue Ye Xue Za Zhi; 2013 Mar; 34(3):190-4. PubMed ID: 23683413
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.